{"response": {"status": "ok", "userTier": "developer", "total": 1, "content": {"id": "business/2007/sep/21/4", "type": "article", "sectionId": "business", "sectionName": "Business", "webPublicationDate": "2007-09-20T23:33:45Z", "webTitle": "Business news in brief", "webUrl": "https://www.theguardian.com/business/2007/sep/21/4", "apiUrl": "https://content.guardianapis.com/business/2007/sep/21/4", "fields": {"headline": "News in brief", "bodyText": "Neuropharm's autism treatment nears US test Neuropharm, the biotechnology company developing a treatment for autism based on fluoxetine, the compound used to make Prozac, said yesterday it was on track to submit the drug to the US food and drug administration by the end of 2008. Robert Mansfield, the chief executive, added that the company had also made good progress on its earlier-stage portfolio, which includes the start of a trial in paediatric obsessive compulsive disorder. The news came as Neuropharm posted its maiden full-year results, with a pre-tax loss of \u00a33.2m. Shares in the company rose 1.5p to 187.5p. Marianne Barriaux Unilever to cut 300 jobs at three factories in UK Unilever is to cut more than 300 jobs at three of its UK factories and review the future of three other sites. Around 315 posts will be lost at Burton, Warrington and Port Sunlight. The consumer products group also announced reviews at its plants in Purfleet, Leeds and Crumlin. \"The proposed changes reflect the opportunities Unilever sees to go further and faster in increasing supply-chain efficiency and responsiveness and to really accelerate the transformation of the UK business,\" the company said. It announced last month that it would cut 20,000 jobs around the world over the next four years. Press Association"}, "isHosted": false, "pillarId": "pillar/news", "pillarName": "News"}}}